These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1344 related items for PubMed ID: 29576505

  • 1. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F, EXPAND Clinical Investigators.
    Lancet; 2018 Mar 31; 391(10127):1263-1273. PubMed ID: 29576505
    [Abstract] [Full Text] [Related]

  • 2. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators.
    Lancet; 2016 Mar 12; 387(10023):1075-1084. PubMed ID: 26827074
    [Abstract] [Full Text] [Related]

  • 3. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E.
    Lancet Neurol; 2013 Aug 12; 12(8):756-67. PubMed ID: 23764350
    [Abstract] [Full Text] [Related]

  • 4. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH, Bar-Or A, Cohan SL, Lublin FD, Coyle PK, Cree BA, Meng X, Su W, Cox GM, Fox RJ.
    Mult Scler Relat Disord; 2023 Jul 12; 75():104766. PubMed ID: 37245350
    [Abstract] [Full Text] [Related]

  • 5. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.
    Neurology; 2021 Jan 19; 96(3):e376-e386. PubMed ID: 33328324
    [Abstract] [Full Text] [Related]

  • 6. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP, Neofidov NA, Bakhtiyarova KZ, Davydovskaya MV, Kairbekova EI, Kolontareva YM, Malkova NA, Odinak MM, Popova EV, Sazonov DV, Stolyarov ID, Smagina IV, Fedyanin AS, Habirov FA, Khaibullin TI, Khachanova NV, Shchukin IA, Boyko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019 Jan 19; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD, SPI2 investigative teams.
    Lancet Neurol; 2020 Dec 19; 19(12):988-997. PubMed ID: 33222767
    [Abstract] [Full Text] [Related]

  • 8. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC.
    J Neurol; 2022 Sep 19; 269(9):5093-5104. PubMed ID: 35639197
    [Abstract] [Full Text] [Related]

  • 9. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
    Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.
    JAMA Neurol; 2016 Sep 01; 73(9):1089-98. PubMed ID: 27380540
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, Kappos L.
    Mult Scler; 2022 Sep 01; 28(10):1591-1605. PubMed ID: 35380078
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL.
    Lancet Neurol; 2020 Dec 01; 19(12):998-1009. PubMed ID: 33129442
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 01; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 13. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ.
    CNS Drugs; 2020 Nov 01; 34(11):1191-1200. PubMed ID: 33108633
    [Abstract] [Full Text] [Related]

  • 14. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators.
    Lancet Neurol; 2018 May 01; 17(5):405-415. PubMed ID: 29545067
    [Abstract] [Full Text] [Related]

  • 15. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA, Worthington E, Haltner A, Cameron C, Nicholas R, Rouyrre N, Dahlke F, Adlard N.
    Curr Med Res Opin; 2020 Jul 01; 36(7):1157-1166. PubMed ID: 32220214
    [Abstract] [Full Text] [Related]

  • 16. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Jul 01; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 17. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS, Kolontareva YM.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021 Jul 01; 121(7):124-129. PubMed ID: 34460168
    [Abstract] [Full Text] [Related]

  • 18. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A, Adlard N, Schwenkglenks M.
    Pharmacoeconomics; 2021 May 01; 39(5):563-577. PubMed ID: 33791945
    [Abstract] [Full Text] [Related]

  • 19. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A.
    Drug Des Devel Ther; 2017 May 01; 11():3153-3157. PubMed ID: 29138536
    [Abstract] [Full Text] [Related]

  • 20. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S, Woodhouse F, Vudumula U, Gudala K, Duddy M, Kroes M.
    J Med Econ; 2022 May 01; 25(1):669-678. PubMed ID: 35575251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.